Status:
COMPLETED
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Lead Sponsor:
ThromboGenics
Conditions:
Vitrectomy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
Eligibility Criteria
Inclusion
- Patients in whom vitrectomy is indicated
Exclusion
- Posterior Vitreous Detachment (PVD) present at baseline
- Vitreous hemorrhage
- Certain vitreoretinal conditions including proliferative disease, rhegmatogenous retinal detachment, and proliferative vitreoretinopathy (PVR)
- Have had a vitrectomy in the study eye at any time
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00412958
Start Date
December 1 2006
End Date
October 1 2008
Last Update
December 17 2014
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Centers, P.C.
Tucson, Arizona, United States, 85704
2
VMR Institute
Huntington Beach, California, United States, 92647
3
Jules Stein Eye Institute/UCLA
Los Angeles, California, United States, 90095
4
Retinal Consultants of San Diego
Poway, California, United States, 92064